Yahoo Finance

TearClear announces the successful initiation of its TC-002 Latanoprost Ophthalmic Solution Phase 3 trial

BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- TearClear, a late clinical stage ophthalmic pharmaceutical company, is pleased to announce the TC-002 Phase 3 trial has been successfully initiated. TearClear ...
Nature

Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma

Aims To compare the diurnal intraocular pressure (IOP) efficacy and safety of timolol vslatanoprost in subjects with exfoliation glaucoma (XFG). Methods A 3-month prospective, single-masked, ...
Healio

TearClear initiates phase 3 trial of preservative-free latanoprost

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. TearClear has initiated a phase 3 trial evaluating ...
Yahoo Finance

TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for the Treatment of Glaucoma with TC-002 (latanoprost ophthalmic solution 0.005%)

CHICAGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- TearClear, an ophthalmic pharmaceutical company that transforms trusted drugs into branded best-in-class therapies, announced today that the company’s lead ...
Medical News Today

Latanoprost and cost

Latanoprost is a generic prescription medication. The Food and Drug Administration (FDA) has approved it to treat increased pressure in the eyes. The drug is for use in adults who have either ...
Business Wire

Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results

IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ...
Healio

Global studies find latanoprost more effective than timolol

UPPSALA, Sweden — Latanoprost (Xalatan, Pharmacia Corp.) reduced diurnal intraocular pressure (IOP) significantly more than timolol, according to a meta-analysis of eight global randomized trials, ...
Business Wire

Aerie Pharmaceuticals Completes Enrollment of Mercury 2 Phase 3 Registration Trial of Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%

In September 2016, the Company reported the successful topline efficacy results from the first Phase 3 registration trial for Roclatan™ ophthalmic solution, “Mercury 1,” which achieved its primary ...
WAVY-TV

TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for the Treatment of Glaucoma with TC-002 (latanoprost ophthalmic solution 0.005%)

TC-002 is the first of four proprietary glaucoma drugs in the TearClear near term pipeline CHICAGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- TearClear, an ophthalmic pharmaceutical company that transforms ...